The Pharmacotherapy Implications of Ventricular Assist Device in the Patient With End-Stage Heart Failure

• Published in: Journal of Pharmacy Practice 2012-04, Vol.25 (2), p.232-249
• Main Authors: Ruden, Serena A. S. Von, Murray, Margaret A., Grice, Jennifer L., Proebstle, Amy K., Kopacek, Karen J.
• Format: Article
• Language: English
• Subjects: Community Pharmacy Services - standards; Heart Failure - therapy; Heart-Assist Devices - adverse effects; Humans; Pharmacists; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Ventricular Function - physiology
• ISSN: 0897-1900; 1531-1937
• DOI: 10.1177/0897190011431635

Advances in mechanical circulatory support, such as the use of ventricular assist devices (VADs), have become a means for prolonging survival in end-stage heart failure (HF). VADs decrease the symptoms of HF and improve quality of life by replacing some of the work of a failing heart. They unload the ventricle to provide improved cardiac output and end-organ perfusion, resulting in improvement in cardiorenal syndromes and New York Heart Association functional class rating. VADs are currently used as a bridge to heart transplantation, a bridge to recovery of cardiac function, or as destination therapy. Complications of VAD include bleeding, infections, arrhythmias, multiple organ failure, right ventricular failure, and neurological dysfunction. Patients with VAD have unique pharmacotherapeutic requirements in terms of anticoagulation, appropriate antibiotic selection, and continuation of HF medications. Pharmacists in acute care and community settings are well prepared to care for the patient with VAD. These patients require thorough counseling and follow-up with regard to prevention and treatment of infections, appropriate levels of anticoagulation, and maintenance of fluid balance. A basic understanding of this unique therapy can assist pharmacists in attending to the needs of patients with VAD.